Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
gut microbiota1104 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A04238 | 33693866 | J Nutr | Hepatoprotective Effects of Indole, a Gut Microbial Metabolite, in Leptin-Deficient Obese Mice. | 2021 | Details |
| A04262 | 33685078 | Zhonghua Gan Zang Bing Za Zhi | [Ten years of research progress in the field of non-viral liver disease]. | 2021 | Details |
| A04278 | 33679403 | Front Pharmacol | Ginsenosides Improve Nonalcoholic Fatty Liver Disease via Integrated Regulation of Gut Microbiota, Inflammation and Energy Homeostasis. | 2021 | Details |
| A04284 | 33678110 | Gut Microbes | Akkermansia muciniphila and environmental enrichment reverse cognitive impairment associated with high-fat high-cholesterol consumption in rats. | 2022 | Details |
| A04285 | 33678036 | Hum Exp Toxicol | Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. | 2021 | Details |
| A04352 | 33652261 | Biomed Pharmacother | Akebia saponin D ameliorates metabolic syndrome (MetS) via remodeling gut microbiota and attenuating intestinal barrier injury. | 2021 | Details |
| A04391 | 33637088 | Lipids Health Dis | Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis. | 2021 | Details |
| A04394 | 33636349 | Pharmacol Res | Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. | 2021 | Details |
| A04410 | 33629536 | Mol Nutr Food Res | Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial. | 2021 | Details |
| A04420 | 33622853 | mSystems | Impaired Intestinal Akkermansia muciniphila and Aryl Hydrocarbon Receptor Ligands Contribute to Nonalcoholic Fatty Liver Disease in Mice. | 2021 | Details |
| A04456 | 33609303 | Hepatology | Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling. | 2021 | Details |
| A04480 | 33601157 | J Pharm Biomed Anal | Therapeutic potential of puerarin against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis determined by combination of 1H NMR spectroscopy-based metabonomics and 16S rRNA gene sequencing. | 2021 | Details |
| A04489 | 33598160 | Food Sci Nutr | The protective effect of sulforaphane on type II diabetes induced by high-fat diet and low-dosage streptozotocin. | 2020 | Details |
| A04537 | 33584555 | Front Microbiol | The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study. | 2021 | Details |
| A04564 | 33578800 | Cancers (Basel) | Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. | 2021 | Details |
| A04587 | 33572481 | J Clin Med | Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives. | 2021 | Details |
| A04600 | 33567710 | Int J Environ Res Public Health | Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. | 2021 | Details |
| A04618 | 33561256 | J Nutr | Dietary Fruit and Vegetable Supplementation Suppresses Diet-Induced Atherosclerosis in LDL Receptor Knockout Mice. | 2021 | Details |
| A04619 | 33560577 | Mol Nutr Food Res | Three Novel Dietary Phenolic Compounds from Pickled Raphanus Sativus L. Inhibit Lipid Accumulation in Obese Mice by Modulating the Gut Microbiota Composition. | 2021 | Details |
| A04623 | 33559369 | Mol Nutr Food Res | Black Current Anthocyanins Improve Lipid Metabolism and Modulate Gut Microbiota in High-Fat Diet-Induced Obese Mice. | 2021 | Details |
| A04668 | 33546191 | Biomedicines | Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. | 2021 | Details |
| A04716 | 33530440 | J Clin Med | NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. | 2021 | Details |
| A04728 | 33525625 | Molecules | The Protective Role of Butyrate against Obesity and Obesity-Related Diseases. | 2021 | Details |
| A04736 | 33520569 | Biosci Microbiota Food Health | Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A04774 | 33510856 | Comput Struct Biotechnol J | Active phase prebiotic feeding alters gut microbiota, induces weight-independent alleviation of hepatic steatosis and serum cholesterol in high-fat diet-fed mice. | 2020 | Details |
| A04793 | 33505139 | World J Gastroenterol | Gut microbiota mediated molecular events and therapy in liver diseases. | 2020 | Details |
| A04830 | 33491316 | Obesity (Silver Spring) | Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A04833 | 33490737 | Hepatoma Res | Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. | 2021 | Details |
| A04840 | 33488295 | Mediators Inflamm | Associations among Dietary Omega-3 Polyunsaturated Fatty Acids, the Gut Microbiota, and Intestinal Immunity. | 2021 | Details |
| A04849 | 33485064 | Biomed Pharmacother | Crosstalk between PPARs and gut microbiota in NAFLD. | 2021 | Details |
| A04854 | 33482026 | Aliment Pharmacol Ther | Cross-linkage between bacterial taxonomy and gene functions: a study of metagenome-assembled genomes of gut microbiota in adult non-alcoholic fatty liver disease. | 2021 | Details |
| A04861 | 33477939 | Microorganisms | Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). | 2021 | Details |
| A04874 | 33471632 | Am J Physiol Gastrointest Liver Physiol | Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis? | 2021 | Details |
| A04934 | 33444725 | J Ethnopharmacol | Anti-NAFLD effect of defatted walnut powder extract in high fat diet-induced C57BL/6 mice by modulating the gut microbiota. | 2021 | Details |
| A04999 | 33420074 | Nat Commun | Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. | 2021 | Details |
| A05003 | 33417955 | Life Sci | Sacran, a sulfated polysaccharide, suppresses the absorption of lipids and modulates the intestinal flora in non-alcoholic steatohepatitis model rats. | 2021 | Details |
| A05018 | 33409398 | Transl Gastroenterol Hepatol | Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease. | 2021 | Details |
| A05023 | 33407877 | Biol Sex Differ | Analysis of sex differences in dietary copper-fructose interaction-induced alterations of gut microbial activity in relation to hepatic steatosis. | 2021 | Details |
| A05031 | 33401222 | Biomed Pharmacother | Pure total flavonoids from citrus attenuate non-alcoholic steatohepatitis via regulating the gut microbiota and bile acid metabolism in mice. | 2021 | Details |
| A05034 | 33400402 | J Cell Mol Med | Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation. | 2021 | Details |
| A05037 | 33398776 | Hepatol Int | Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice. | 2021 | Details |
| A05062 | 33390939 | Front Pharmacol | Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-Mψ-Nuclear Factor-κB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice. | 2020 | Details |
| A05088 | 33382431 | J Nutr | Polylactose Exhibits Prebiotic Activity and Reduces Adiposity and Nonalcoholic Fatty Liver Disease in Rats Fed a High-Fat Diet. | 2021 | Details |
| A05096 | 33378048 | Eur Rev Med Pharmacol Sci | Gut microbiota and its metabolic potential. | 2020 | Details |
| A05118 | 33369197 | Mol Nutr Food Res | Punicalagin Prevents Hepatic Steatosis through Improving Lipid Homeostasis and Inflammation in Liver and Adipose Tissue and Modulating Gut Microbiota in Western Diet-Fed Mice. | 2021 | Details |
| A05128 | 33363046 | Front Cell Infect Microbiol | E. coli NF73-1 Isolated From NASH Patients Aggravates NAFLD in Mice by Translocating Into the Liver and Stimulating M1 Polarization. | 2020 | Details |
| A05134 | 33360580 | Environ Pollut | Exposure to nitenpyram during pregnancy causes colonic mucosal damage and non-alcoholic steatohepatitis in mouse offspring: The role of gut microbiota. | 2020 | Details |
| A05185 | 33343508 | Front Endocrinol (Lausanne) | ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue. | 2020 | Details |
| A05194 | 33340925 | Thromb Res | Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. | 2020 | Details |
| A05218 | 33334622 | Arch Med Res | Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A05227 | 33331485 | Arq Gastroenterol | GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). | 2021 | Details |
| A05234 | 33328987 | Front Pharmacol | Da-Chai-Hu Decoction Ameliorates High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Remodeling the Gut Microbiota and Modulating the Serum Metabolism. | 2020 | Details |
| A05269 | 33318628 | Cell Mol Immunol | Gut microbiome, liver immunology, and liver diseases. | 2020 | Details |
| A05273 | 33317254 | Clin Mol Hepatol | Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. | 2020 | Details |
| A05344 | 33293992 | Evid Based Complement Alternat Med | Effect of Sheng-Jiang Powder on Gut Microbiota in High-Fat Diet-Induced NAFLD. | 2020 | Details |
| A05346 | 33292701 | Biomark Res | Dysregulated bile acid receptor-mediated signaling and IL-17A induction are implicated in diet-associated hepatic health and cognitive function. | 2020 | Details |
| A05364 | 33281770 | Front Microbiol | Novel Odoribacter splanchnicus Strain and Its Outer Membrane Vesicles Exert Immunoregulatory Effects in vitro. | 2020 | Details |
| A05450 | 33252713 | Protein Cell | Targeting the alternative bile acid synthetic pathway for metabolic diseases. | 2020 | Details |
| A05473 | 33246225 | Biomed Pharmacother | Akkermansia muciniphila: A potential novel mechanism of nuciferine to improve hyperlipidemia. | 2020 | Details |
| A05527 | 33218081 | Biology (Basel) | Organismal Fructose Metabolism in Health and Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A05568 | 33204402 | Oxid Med Cell Longev | Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NFκB Signaling Pathway and Restores Gut Microbiota in High-Fat-Diet-Fed Mice. | 2020 | Details |
| A05603 | 33193105 | Front Endocrinol (Lausanne) | Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH. | 2020 | Details |
| A05617 | 33186794 | Biomed Pharmacother | Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. | 2020 | Details |
| A05623 | 33185911 | Hepatology | Neutral Ceramidase Mediates Nonalcoholic Steatohepatitis by Regulating Monounsaturated Fatty Acids and Gut IgA+ B Cells. | 2021 | Details |
| A05628 | 33183606 | Carbohydr Polym | Friend or foe? The roles of inulin-type fructans. | 2020 | Details |
| A05630 | 33182700 | Nutrients | Fructose-Induced Intestinal Microbiota Shift Following Two Types of Short-Term High-Fructose Dietary Phases. | 2020 | Details |
| A05635 | 33180143 | Eur J Nutr | A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier. | 2020 | Details |
| A05642 | 33177790 | World J Gastroenterol | Role of gut microbiota via the gut-liver-brain axis in digestive diseases. | 2020 | Details |
| A05700 | 33150145 | J Hepatocell Carcinoma | Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. | 2020 | Details |
| A05728 | 33142346 | Planta Med | Brown-Algae Polysaccharides as Active Constituents against Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A05752 | 33132636 | World J Gastroenterol | Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis? | 2020 | Details |
| A05764 | 33127939 | Sci Rep | Supplementation of branched-chain amino acids decreases fat accumulation in the liver through intestinal microbiota-mediated production of acetic acid. | 2020 | Details |
| A05786 | 33117316 | Front Microbiol | Microbial Metabolites: Critical Regulators in NAFLD. | 2020 | Details |
| A05803 | 33114130 | Nutrients | Bilberry Anthocyanins Ameliorate NAFLD by Improving Dyslipidemia and Gut Microbiome Dysbiosis. | 2020 | Details |
| A05829 | 33105554 | Nutrients | Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats. | 2020 | Details |
| A05977 | 33053942 | Clin Mol Hepatol | Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights. | 2020 | Details |
| A05981 | 33053631 | Nutrients | Microbiota, Fiber, and NAFLD: Is There Any Connection? | 2020 | Details |
| A05985 | 33050862 | Curr Pharm Biotechnol | Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review. | 2022 | Details |
| A06022 | 33036939 | Surg Obes Relat Dis | Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery. | 2020 | Details |
| A06030 | 33034193 | J Agric Food Chem | High-Fat Proteins Drive Dynamic Changes in Gut Microbiota, Hepatic Metabolome, and Endotoxemia-TLR-4-NFκB-Mediated Inflammation in Mice. | 2020 | Details |
| A06056 | 33026380 | Food Funct | Gut inflammation exacerbates hepatic injury in C57BL/6J mice via gut-vascular barrier dysfunction with high-fat-incorporated meat protein diets. | 2020 | Details |
| A06060 | 33024915 | Hepatol Commun | Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice. | 2020 | Details |
| A06072 | 33017572 | Life Sci | Nonalcoholic fatty liver disease and colorectal cancer: Correlation and missing links. | 2020 | Details |
| A06116 | 32999906 | GE Port J Gastroenterol | Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. | 2020 | Details |
| A06139 | 32992082 | Phytomedicine | Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse. | 2020 | Details |
| A06160 | 32982365 | Clin Exp Gastroenterol | Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats. | 2020 | Details |
| A06195 | 32973925 | Therap Adv Gastroenterol | The role of the gut microbiome and exercise in non-alcoholic fatty liver disease. | 2020 | Details |
| A06196 | 32973715 | Front Microbiol | Constant Light Exposure Alters Gut Microbiota and Promotes the Progression of Steatohepatitis in High Fat Diet Rats. | 2020 | Details |
| A06319 | 32930860 | Wien Klin Wochenschr | Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. | 2020 | Details |
| A06327 | 32927776 | Nutrients | New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. | 2020 | Details |
| A06339 | 32923658 | Cannabis Cannabinoid Res | Cannabis Extracts Affected Metabolic Syndrome Parameters in Mice Fed High-Fat/Cholesterol Diet. | 2020 | Details |
| A06359 | 32916966 | Microorganisms | Disease, Drugs and Dysbiosis: Understanding Microbial Signatures in Metabolic Disease and Medical Interventions. | 2020 | Details |
| A06385 | 32900869 | mSystems | Dietary Intervention Reverses Fatty Liver and Altered Gut Microbiota during Early-Life Undernutrition. | 2020 | Details |
| A06395 | 32895402 | Sci Rep | Long-term effects of western diet consumption in male and female mice. | 2020 | Details |
| A06400 | 32892668 | Expert Rev Gastroenterol Hepatol | Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver. | 2020 | Details |
| A06502 | 32850884 | Front Med (Lausanne) | Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. | 2020 | Details |
| A06521 | 32841652 | J Allergy Clin Immunol | Regulating metabolic inflammation by nutritional modulation. | 2020 | Details |
| A06558 | 32825440 | Int J Mol Sci | Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. | 2020 | Details |
| A06567 | 32823983 | J Clin Med | Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. | 2020 | Details |
| A06568 | 32823659 | Int J Mol Sci | Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. | 2020 | Details |